替加环素对脆弱拟杆菌群的体外活性。
In vitro activities of tigecycline against the Bacteroides fragilis group.
作者信息
Jacobus N V, McDermott L A, Ruthazer R, Snydman D R
机构信息
Department of Medicine, Tufts-New England Medical Center, Boston, Massachusetts 02111, USA.
出版信息
Antimicrob Agents Chemother. 2004 Mar;48(3):1034-6. doi: 10.1128/AAC.48.3.1034-1036.2004.
Abstract
The in vitro activities of tigecycline were tested against 831 isolates of the Bacteroides fragilis group representing all of the species within the group. On a weight-to-weight basis (8 microg/ml), tigecycline was more active than clindamycin, minocycline, trovafloxacin, and cefoxitin and less active than imipenem or piperacillin-tazobactam against all isolates of the B. fragilis group. Tigecycline geometric mean MICs were statistically higher against B. distasonis than other Bacteroides species (P value of 0.0001).
摘要
针对代表脆弱拟杆菌群内所有物种的831株脆弱拟杆菌群菌株，测试了替加环素的体外活性。以重量对重量计（8微克/毫升），替加环素对所有脆弱拟杆菌群菌株的活性高于克林霉素、米诺环素、曲伐沙星和头孢西丁，而低于亚胺培南或哌拉西林-他唑巴坦。替加环素的几何平均最低抑菌浓度（MIC）对狄氏拟杆菌的统计学结果高于其他拟杆菌属物种（P值为0.0001）。
相似文献
1
In vitro activities of tigecycline against the Bacteroides fragilis group.替加环素对脆弱拟杆菌群的体外活性。
Antimicrob Agents Chemother. 2004 Mar;48(3):1034-6. doi: 10.1128/AAC.48.3.1034-1036.2004.
2
In vitro activity of tigecycline against Bacteroides species.替加环素对拟杆菌属细菌的体外活性。
J Antimicrob Chemother. 2005 Aug;56(2):349-52. doi: 10.1093/jac/dki197. Epub 2005 Jun 10.
3
National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.脆弱拟杆菌群药敏全国调查：1997年至2004年美国趋势报告与分析
Antimicrob Agents Chemother. 2007 May;51(5):1649-55. doi: 10.1128/AAC.01435-06. Epub 2007 Feb 5.
4
Geographic patterns of antimicrobial susceptibilities for Bacteroides spp. worldwide: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2007-2020.全球范围内脆弱拟杆菌属对抗菌药物敏感性的地理模式：来自 2007-2020 年抗菌药物检测领导和监测（ATLAS）计划的结果。
Int J Antimicrob Agents. 2023 Jul;62(1):106822. doi: 10.1016/j.ijantimicag.2023.106822. Epub 2023 Apr 21.
5
Prevalence of antimicrobial resistance among clinical isolates of Bacteroides fragilis group in Canada in 2010-2011: CANWARD surveillance study.2010-2011 年加拿大脆弱拟杆菌群临床分离株的抗菌药物耐药性流行情况：CANWARD 监测研究。
Antimicrob Agents Chemother. 2012 Mar;56(3):1247-52. doi: 10.1128/AAC.05823-11. Epub 2011 Dec 27.
6
Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.脆弱拟杆菌群物种及其他厌氧菌对美罗培南、亚胺培南、哌拉西林、头孢西丁、氨苄西林/舒巴坦、克林霉素和甲硝唑的敏感性比较。
J Antimicrob Chemother. 1993 Mar;31(3):363-72. doi: 10.1093/jac/31.3.363.
7
Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007).从厌氧菌调查中吸取的教训：历史透视和对最新数据（2005-2007 年）的回顾。
Clin Infect Dis. 2010 Jan 1;50 Suppl 1:S26-33. doi: 10.1086/647940.
8
Survey of Bacteroides fragilis group susceptibility patterns in Canada.加拿大脆弱拟杆菌群药敏模式调查。
Antimicrob Agents Chemother. 1992 Feb;36(2):343-7. doi: 10.1128/AAC.36.2.343.
9
Resistance trends of Bacteroides fragilis group over an 8-year period, 1997-2004, in Korea.1997年至2004年韩国8年间脆弱拟杆菌群的耐药趋势
Korean J Lab Med. 2009 Aug;29(4):293-8. doi: 10.3343/kjlm.2009.29.4.293.
10
Activity of newer beta-lactam agents against clinical isolates of Bacteroides fragilis and other Bacteroides species.新型β-内酰胺类药物对脆弱拟杆菌及其他拟杆菌属临床分离株的活性。
Antimicrob Agents Chemother. 1987 Dec;31(12):2002-4. doi: 10.1128/AAC.31.12.2002.
引用本文的文献
1
Multicenter study of antimicrobial susceptibility of anaerobic bacteria in Korea in 2012.2012年韩国厌氧菌抗菌药敏性多中心研究。
Ann Lab Med. 2015 Sep;35(5):479-86. doi: 10.3343/alm.2015.35.5.479.
2
Tigecycline treatment causes a decrease in fibrinogen levels.替加环素治疗会导致纤维蛋白原水平降低。
Antimicrob Agents Chemother. 2015 Mar;59(3):1650-5. doi: 10.1128/AAC.04305-14. Epub 2014 Dec 29.
3
Antianaerobic antimicrobials: spectrum and susceptibility testing.抗厌氧微生物药物：谱和药敏试验。
Clin Microbiol Rev. 2013 Jul;26(3):526-46. doi: 10.1128/CMR.00086-12.
4
5
Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.1997年至2006年期间，西班牙马德里脆弱拟杆菌群的耐药趋势。
Antimicrob Agents Chemother. 2008 Jul;52(7):2686-90. doi: 10.1128/AAC.00081-08. Epub 2008 May 12.
6
Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence.替加环素治疗多重耐药（包括耐碳青霉烯类）鲍曼不动杆菌感染：科学证据综述
J Antimicrob Chemother. 2008 Jul;62(1):45-55. doi: 10.1093/jac/dkn165. Epub 2008 Apr 24.
7
In vitro activity of ten antibiotics, including tigecycline, against Bacteroides species in Austria.
Eur J Clin Microbiol Infect Dis. 2007 Jul;26(7):525-7. doi: 10.1007/s10096-007-0318-0.
8
Effect of tigecycline on normal oropharyngeal and intestinal microflora.替加环素对正常口咽和肠道微生物群的影响。
Antimicrob Agents Chemother. 2006 Oct;50(10):3375-80. doi: 10.1128/AAC.00373-06.
9
Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents.396株罕见厌氧菌株对替加环素和其他八种抗菌药物的体外敏感性比较
Antimicrob Agents Chemother. 2006 Oct;50(10):3507-13. doi: 10.1128/AAC.00499-06. Epub 2006 Aug 28.
10
Tigecycline.替加环素
Drugs. 2005;65(18):2623-35; discussion 2636-7. doi: 10.2165/00003495-200565180-00008.
本文引用的文献
1
In vitro activities of newer quinolones against bacteroides group organisms.新型喹诺酮类药物对拟杆菌属微生物的体外活性。
Antimicrob Agents Chemother. 2002 Oct;46(10):3276-9. doi: 10.1128/AAC.46.10.3276-3279.2002.
2
In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.替加环素（GAR-936）、达托霉素及其他对照抗菌药物对糖肽类中介金黄色葡萄球菌及其他耐药革兰氏阳性病原体的体外和体内活性。
Antimicrob Agents Chemother. 2002 Aug;46(8):2595-601. doi: 10.1128/AAC.46.8.2595-2601.2002.
3
In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain.替加环素（GAR-936）对西班牙近期分离的临床细菌的体外活性。
Antimicrob Agents Chemother. 2002 Mar;46(3):892-5. doi: 10.1128/AAC.46.3.892-895.2002.
4
Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species.脆弱拟杆菌群、普雷沃菌属、梭杆菌属、卟啉单胞菌属和消化链球菌属临床分离株体外抗菌药敏变化的多中心调查。
Antimicrob Agents Chemother. 2001 Apr;45(4):1238-43. doi: 10.1128/AAC.45.4.1238-1243.2001.
5
In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline.厌氧细菌对新型甘氨酰环素GAR-936的体外敏感性
Clin Microbiol Infect. 2000 Mar;6(3):159-63. doi: 10.1046/j.1469-0691.2000.00034-6.x.
6
Comparative in vitro activities of clinafloxacin and trovafloxacin against 1,000 isolates of bacteroides fragilis group: effect of the medium on test results.克林沙星与曲伐沙星对1000株脆弱拟杆菌属菌株的体外活性比较：培养基对试验结果的影响
Antimicrob Agents Chemother. 2000 Jun;44(6):1710-2. doi: 10.1128/AAC.44.6.1710-1712.2000.
7
Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.新型甘氨酰环素GAR-936对1203株近期临床分离细菌的抗菌活性及抗菌谱
Diagn Microbiol Infect Dis. 2000 Jan;36(1):19-36. doi: 10.1016/s0732-8893(99)00092-9.
8
In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).新型甘氨酰环素（米诺环素的9-叔丁基甘氨酰胺衍生物，GAR-936）的体外和体内抗菌活性
Antimicrob Agents Chemother. 1999 Apr;43(4):738-44. doi: 10.1128/AAC.43.4.738.
9
Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994.1990年至1994年间脆弱拟杆菌群临床分离株抗菌药物耐药模式的趋势分析。
Clin Infect Dis. 1996 Dec;23 Suppl 1:S54-65. doi: 10.1093/clinids/23.supplement_1.s54.
10
In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines.新型半合成四环素类——甘氨酰环素的体外和体内抗菌活性
Antimicrob Agents Chemother. 1993 Nov;37(11):2270-7. doi: 10.1128/AAC.37.11.2270.
Zotero 插件